Sequana Medical NV (Euronext Brussels: SEQUA (the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today ...

Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without treatment, there is a significant risk of complications that are life threatening and require ...

Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without ...

What is the aim of this Cochrane review? To find out the best available treatment for ascites (abnormal build-up of fluid in the tummy) in people with advanced liver disease (liver cirrhosis, or ...

Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

Introduction: In patients with heart failure, the relationship between systolic dysfunction, intra-abdominal pressure (IAP), and renal function are only beginning to be understood. Limited single ...

New research has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body's immune response in advanced ovarian cancer. The findings offer new ...

CMS Approves Additional Payment for Sequana Medical's alfapump® system in Hospital Inpatient Cases alfapump® New Technology Add-on Payment (NTAP) Included in CMS Final Fiscal Year 2026 Rule and in ...